BlossomHill Therapeutics (NASDAQ:BLSM – Get Free Report) was upgraded by investment analysts at Wall Street Zen to a “hold” rating in a research report issued on Saturday.
BlossomHill Therapeutics Price Performance
BlossomHill Therapeutics stock opened at $16.18 on Friday. BlossomHill Therapeutics has a twelve month low of $15.25 and a twelve month high of $17.25.
Insiders Place Their Bets
In other news, Director Carl L. Gordon bought 625,000 shares of BlossomHill Therapeutics stock in a transaction dated Monday, August 10th. The shares were acquired at an average price of $16.00 per share, with a total value of $10,000,000.00. Following the completion of the purchase, the director owned 2,714,279 shares in the company, valued at $43,428,464. The trade was a 29.91% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Bihua Chen bought 312,500 shares of the stock in a transaction dated Monday, August 10th. The stock was purchased at an average price of $16.00 per share, with a total value of $5,000,000.00. Following the acquisition, the director directly owned 3,614,034 shares in the company, valued at approximately $57,824,544. The trade was a 9.47% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders have bought 1,573,900 shares of company stock valued at $25,181,900.
About BlossomHill Therapeutics
BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.
Read More
- Five stocks we like better than BlossomHill Therapeutics
- The Metals Company’s Big Bet Now Comes Down to a License
- OneSpaWorld Keeps Turning Cruise Demand Into Record Earnings
- Meta and Tesla Are Rebounding From Oversold Levels—Now What?
- AMG’s Alternatives Boom Powers Record Growth
Receive News & Ratings for BlossomHill Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BlossomHill Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
